nodes	percent_of_prediction	percent_of_DWPC	metapath
Regadenoson—Electrocardiogram QT corrected interval prolonged—Vandetanib—thyroid cancer	0.0565	0.057	CcSEcCtD
Regadenoson—Respiratory arrest—Vandetanib—thyroid cancer	0.0346	0.0349	CcSEcCtD
Regadenoson—Altered state of consciousness—Vandetanib—thyroid cancer	0.033	0.0332	CcSEcCtD
Regadenoson—Faecal incontinence—Vandetanib—thyroid cancer	0.0302	0.0304	CcSEcCtD
Regadenoson—Transient ischaemic attack—Vandetanib—thyroid cancer	0.0302	0.0304	CcSEcCtD
Regadenoson—Ischaemia—Sorafenib—thyroid cancer	0.0281	0.0284	CcSEcCtD
Regadenoson—Electrocardiogram QT prolonged—Vandetanib—thyroid cancer	0.0237	0.0239	CcSEcCtD
Regadenoson—Ventricular arrhythmia—Vandetanib—thyroid cancer	0.0206	0.0207	CcSEcCtD
Regadenoson—Transient ischaemic attack—Sorafenib—thyroid cancer	0.0203	0.0205	CcSEcCtD
Regadenoson—Electrocardiogram ST segment depression—Epirubicin—thyroid cancer	0.0167	0.0169	CcSEcCtD
Regadenoson—Respiratory distress—Sorafenib—thyroid cancer	0.0162	0.0163	CcSEcCtD
Regadenoson—Electrocardiogram ST segment depression—Doxorubicin—thyroid cancer	0.0155	0.0156	CcSEcCtD
Regadenoson—Depressed level of consciousness—Vandetanib—thyroid cancer	0.0147	0.0148	CcSEcCtD
Regadenoson—Myocardial ischaemia—Sorafenib—thyroid cancer	0.0128	0.0129	CcSEcCtD
Regadenoson—Atrial fibrillation—Vandetanib—thyroid cancer	0.0117	0.0118	CcSEcCtD
Regadenoson—Cardiac arrest—Vandetanib—thyroid cancer	0.0105	0.0106	CcSEcCtD
Regadenoson—Bronchospasm—Vandetanib—thyroid cancer	0.00939	0.00947	CcSEcCtD
Regadenoson—Renal failure—Vandetanib—thyroid cancer	0.00837	0.00844	CcSEcCtD
Regadenoson—Adenosine triphosphate—AKT1—thyroid cancer	0.0082	1	CrCbGaD
Regadenoson—Bradycardia—Vandetanib—thyroid cancer	0.00778	0.00785	CcSEcCtD
Regadenoson—Pain in extremity—Sorafenib—thyroid cancer	0.00745	0.00752	CcSEcCtD
Regadenoson—Eye disorder—Vandetanib—thyroid cancer	0.00714	0.0072	CcSEcCtD
Regadenoson—Cardiac disorder—Vandetanib—thyroid cancer	0.0071	0.00715	CcSEcCtD
Regadenoson—Angiopathy—Vandetanib—thyroid cancer	0.00694	0.00699	CcSEcCtD
Regadenoson—Mediastinal disorder—Vandetanib—thyroid cancer	0.00689	0.00695	CcSEcCtD
Regadenoson—Mental disorder—Vandetanib—thyroid cancer	0.0067	0.00675	CcSEcCtD
Regadenoson—Dysgeusia—Vandetanib—thyroid cancer	0.00652	0.00657	CcSEcCtD
Regadenoson—Vision blurred—Vandetanib—thyroid cancer	0.00627	0.00632	CcSEcCtD
Regadenoson—Tremor—Vandetanib—thyroid cancer	0.00624	0.00629	CcSEcCtD
Regadenoson—Abdominal discomfort—Sorafenib—thyroid cancer	0.00618	0.00623	CcSEcCtD
Regadenoson—Loss of consciousness—Vandetanib—thyroid cancer	0.00585	0.0059	CcSEcCtD
Regadenoson—Cough—Vandetanib—thyroid cancer	0.00581	0.00586	CcSEcCtD
Regadenoson—Convulsion—Vandetanib—thyroid cancer	0.00577	0.00581	CcSEcCtD
Regadenoson—Hypertension—Vandetanib—thyroid cancer	0.00575	0.00579	CcSEcCtD
Regadenoson—Chest pain—Vandetanib—thyroid cancer	0.00567	0.00571	CcSEcCtD
Regadenoson—Arthralgia—Vandetanib—thyroid cancer	0.00567	0.00571	CcSEcCtD
Regadenoson—Acute coronary syndrome—Sorafenib—thyroid cancer	0.00566	0.00571	CcSEcCtD
Regadenoson—Renal failure—Sorafenib—thyroid cancer	0.00565	0.00569	CcSEcCtD
Regadenoson—Anxiety—Vandetanib—thyroid cancer	0.00565	0.00569	CcSEcCtD
Regadenoson—Myocardial infarction—Sorafenib—thyroid cancer	0.00563	0.00568	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00563	0.00567	CcSEcCtD
Regadenoson—Nervous system disorder—Vandetanib—thyroid cancer	0.00533	0.00537	CcSEcCtD
Regadenoson—Skin disorder—Vandetanib—thyroid cancer	0.00528	0.00532	CcSEcCtD
Regadenoson—Ventricular arrhythmia—Epirubicin—thyroid cancer	0.00513	0.00517	CcSEcCtD
Regadenoson—Connective tissue disorder—Sorafenib—thyroid cancer	0.00507	0.00511	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00495	0.00499	CcSEcCtD
Regadenoson—Insomnia—Vandetanib—thyroid cancer	0.00491	0.00495	CcSEcCtD
Regadenoson—Paraesthesia—Vandetanib—thyroid cancer	0.00488	0.00492	CcSEcCtD
Regadenoson—Dyspnoea—Vandetanib—thyroid cancer	0.00484	0.00488	CcSEcCtD
Regadenoson—Feeling hot—Epirubicin—thyroid cancer	0.00484	0.00488	CcSEcCtD
Regadenoson—Tinnitus—Sorafenib—thyroid cancer	0.00481	0.00485	CcSEcCtD
Regadenoson—Flushing—Sorafenib—thyroid cancer	0.00479	0.00483	CcSEcCtD
Regadenoson—Cardiac disorder—Sorafenib—thyroid cancer	0.00479	0.00483	CcSEcCtD
Regadenoson—Ventricular arrhythmia—Doxorubicin—thyroid cancer	0.00474	0.00478	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00469	0.00473	CcSEcCtD
Regadenoson—Angiopathy—Sorafenib—thyroid cancer	0.00468	0.00472	CcSEcCtD
Regadenoson—Immune system disorder—Sorafenib—thyroid cancer	0.00466	0.0047	CcSEcCtD
Regadenoson—Injection site pain—Epirubicin—thyroid cancer	0.00465	0.00469	CcSEcCtD
Regadenoson—Mediastinal disorder—Sorafenib—thyroid cancer	0.00465	0.00469	CcSEcCtD
Regadenoson—Pain—Vandetanib—thyroid cancer	0.00464	0.00468	CcSEcCtD
Regadenoson—Mental disorder—Sorafenib—thyroid cancer	0.00452	0.00456	CcSEcCtD
Regadenoson—Erythema—Sorafenib—thyroid cancer	0.00449	0.00453	CcSEcCtD
Regadenoson—Feeling hot—Doxorubicin—thyroid cancer	0.00447	0.00451	CcSEcCtD
Regadenoson—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00444	0.00448	CcSEcCtD
Regadenoson—Dysgeusia—Sorafenib—thyroid cancer	0.0044	0.00443	CcSEcCtD
Regadenoson—Vasodilation procedure—Epirubicin—thyroid cancer	0.00432	0.00436	CcSEcCtD
Regadenoson—Vasodilation—Epirubicin—thyroid cancer	0.00432	0.00436	CcSEcCtD
Regadenoson—Injection site pain—Doxorubicin—thyroid cancer	0.0043	0.00434	CcSEcCtD
Regadenoson—Abdominal pain—Vandetanib—thyroid cancer	0.00429	0.00433	CcSEcCtD
Regadenoson—Angioedema—Sorafenib—thyroid cancer	0.0041	0.00414	CcSEcCtD
Regadenoson—Syncope—Sorafenib—thyroid cancer	0.00403	0.00406	CcSEcCtD
Regadenoson—Vasodilation procedure—Doxorubicin—thyroid cancer	0.004	0.00403	CcSEcCtD
Regadenoson—Vasodilation—Doxorubicin—thyroid cancer	0.004	0.00403	CcSEcCtD
Regadenoson—Loss of consciousness—Sorafenib—thyroid cancer	0.00395	0.00398	CcSEcCtD
Regadenoson—Cough—Sorafenib—thyroid cancer	0.00392	0.00395	CcSEcCtD
Regadenoson—Atrioventricular block—Epirubicin—thyroid cancer	0.00391	0.00394	CcSEcCtD
Regadenoson—Asthenia—Vandetanib—thyroid cancer	0.0039	0.00393	CcSEcCtD
Regadenoson—Hypertension—Sorafenib—thyroid cancer	0.00388	0.00391	CcSEcCtD
Regadenoson—Musculoskeletal pain—Epirubicin—thyroid cancer	0.00384	0.00387	CcSEcCtD
Regadenoson—Arthralgia—Sorafenib—thyroid cancer	0.00382	0.00385	CcSEcCtD
Regadenoson—Myalgia—Sorafenib—thyroid cancer	0.00382	0.00385	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.0038	0.00383	CcSEcCtD
Regadenoson—Diarrhoea—Vandetanib—thyroid cancer	0.00372	0.00375	CcSEcCtD
Regadenoson—Anaphylactic shock—Sorafenib—thyroid cancer	0.00366	0.00369	CcSEcCtD
Regadenoson—Atrioventricular block—Doxorubicin—thyroid cancer	0.00362	0.00365	CcSEcCtD
Regadenoson—Shock—Sorafenib—thyroid cancer	0.0036	0.00363	CcSEcCtD
Regadenoson—Nervous system disorder—Sorafenib—thyroid cancer	0.00359	0.00362	CcSEcCtD
Regadenoson—Dizziness—Vandetanib—thyroid cancer	0.00359	0.00362	CcSEcCtD
Regadenoson—Skin disorder—Sorafenib—thyroid cancer	0.00356	0.00359	CcSEcCtD
Regadenoson—Musculoskeletal pain—Doxorubicin—thyroid cancer	0.00355	0.00358	CcSEcCtD
Regadenoson—Vomiting—Vandetanib—thyroid cancer	0.00345	0.00348	CcSEcCtD
Regadenoson—Rash—Vandetanib—thyroid cancer	0.00342	0.00345	CcSEcCtD
Regadenoson—Dermatitis—Vandetanib—thyroid cancer	0.00342	0.00345	CcSEcCtD
Regadenoson—Headache—Vandetanib—thyroid cancer	0.0034	0.00343	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00334	0.00337	CcSEcCtD
Regadenoson—Dyspnoea—Sorafenib—thyroid cancer	0.00327	0.00329	CcSEcCtD
Regadenoson—Nausea—Vandetanib—thyroid cancer	0.00323	0.00325	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00316	0.00319	CcSEcCtD
Regadenoson—Pain—Sorafenib—thyroid cancer	0.00313	0.00316	CcSEcCtD
Regadenoson—Eye pain—Epirubicin—thyroid cancer	0.00305	0.00308	CcSEcCtD
Regadenoson—Gastrointestinal pain—Sorafenib—thyroid cancer	0.003	0.00302	CcSEcCtD
Regadenoson—Urticaria—Sorafenib—thyroid cancer	0.00291	0.00293	CcSEcCtD
Regadenoson—Abdominal pain—Sorafenib—thyroid cancer	0.0029	0.00292	CcSEcCtD
Regadenoson—Renal impairment—Epirubicin—thyroid cancer	0.00289	0.00292	CcSEcCtD
Regadenoson—Eye pain—Doxorubicin—thyroid cancer	0.00282	0.00285	CcSEcCtD
Regadenoson—Cerebrovascular accident—Epirubicin—thyroid cancer	0.00281	0.00283	CcSEcCtD
Regadenoson—Pain in extremity—Epirubicin—thyroid cancer	0.00275	0.00278	CcSEcCtD
Regadenoson—Hypersensitivity—Sorafenib—thyroid cancer	0.0027	0.00272	CcSEcCtD
Regadenoson—Renal impairment—Doxorubicin—thyroid cancer	0.00268	0.0027	CcSEcCtD
Regadenoson—Asthenia—Sorafenib—thyroid cancer	0.00263	0.00265	CcSEcCtD
Regadenoson—Cardiac arrest—Epirubicin—thyroid cancer	0.00262	0.00264	CcSEcCtD
Regadenoson—Cerebrovascular accident—Doxorubicin—thyroid cancer	0.0026	0.00262	CcSEcCtD
Regadenoson—Pain in extremity—Doxorubicin—thyroid cancer	0.00255	0.00257	CcSEcCtD
Regadenoson—Diarrhoea—Sorafenib—thyroid cancer	0.00251	0.00253	CcSEcCtD
Regadenoson—Cardiac arrest—Doxorubicin—thyroid cancer	0.00242	0.00244	CcSEcCtD
Regadenoson—Dizziness—Sorafenib—thyroid cancer	0.00242	0.00244	CcSEcCtD
Regadenoson—Abdominal distension—Epirubicin—thyroid cancer	0.0024	0.00242	CcSEcCtD
Regadenoson—Asthma—Epirubicin—thyroid cancer	0.00238	0.0024	CcSEcCtD
Regadenoson—Vomiting—Sorafenib—thyroid cancer	0.00233	0.00235	CcSEcCtD
Regadenoson—Angina pectoris—Epirubicin—thyroid cancer	0.00232	0.00234	CcSEcCtD
Regadenoson—Rash—Sorafenib—thyroid cancer	0.00231	0.00233	CcSEcCtD
Regadenoson—Dermatitis—Sorafenib—thyroid cancer	0.00231	0.00233	CcSEcCtD
Regadenoson—Headache—Sorafenib—thyroid cancer	0.0023	0.00231	CcSEcCtD
Regadenoson—Abdominal distension—Doxorubicin—thyroid cancer	0.00222	0.00224	CcSEcCtD
Regadenoson—Asthma—Doxorubicin—thyroid cancer	0.0022	0.00222	CcSEcCtD
Regadenoson—Nausea—Sorafenib—thyroid cancer	0.00218	0.00219	CcSEcCtD
Regadenoson—Angina pectoris—Doxorubicin—thyroid cancer	0.00215	0.00216	CcSEcCtD
Regadenoson—Renal failure—Epirubicin—thyroid cancer	0.00209	0.0021	CcSEcCtD
Regadenoson—Bradycardia—Epirubicin—thyroid cancer	0.00194	0.00196	CcSEcCtD
Regadenoson—Renal failure—Doxorubicin—thyroid cancer	0.00193	0.00195	CcSEcCtD
Regadenoson—Hypoaesthesia—Epirubicin—thyroid cancer	0.0019	0.00191	CcSEcCtD
Regadenoson—Connective tissue disorder—Epirubicin—thyroid cancer	0.00187	0.00189	CcSEcCtD
Regadenoson—Bradycardia—Doxorubicin—thyroid cancer	0.0018	0.00181	CcSEcCtD
Regadenoson—Eye disorder—Epirubicin—thyroid cancer	0.00178	0.0018	CcSEcCtD
Regadenoson—Tinnitus—Epirubicin—thyroid cancer	0.00178	0.00179	CcSEcCtD
Regadenoson—Cardiac disorder—Epirubicin—thyroid cancer	0.00177	0.00178	CcSEcCtD
Regadenoson—Flushing—Epirubicin—thyroid cancer	0.00177	0.00178	CcSEcCtD
Regadenoson—Hypoaesthesia—Doxorubicin—thyroid cancer	0.00175	0.00177	CcSEcCtD
Regadenoson—Connective tissue disorder—Doxorubicin—thyroid cancer	0.00173	0.00175	CcSEcCtD
Regadenoson—Angiopathy—Epirubicin—thyroid cancer	0.00173	0.00174	CcSEcCtD
Regadenoson—Immune system disorder—Epirubicin—thyroid cancer	0.00172	0.00174	CcSEcCtD
Regadenoson—Mediastinal disorder—Epirubicin—thyroid cancer	0.00172	0.00173	CcSEcCtD
Regadenoson—Mental disorder—Epirubicin—thyroid cancer	0.00167	0.00168	CcSEcCtD
Regadenoson—Erythema—Epirubicin—thyroid cancer	0.00166	0.00167	CcSEcCtD
Regadenoson—Eye disorder—Doxorubicin—thyroid cancer	0.00165	0.00166	CcSEcCtD
Regadenoson—Tinnitus—Doxorubicin—thyroid cancer	0.00164	0.00166	CcSEcCtD
Regadenoson—Flushing—Doxorubicin—thyroid cancer	0.00164	0.00165	CcSEcCtD
Regadenoson—Cardiac disorder—Doxorubicin—thyroid cancer	0.00164	0.00165	CcSEcCtD
Regadenoson—Dysgeusia—Epirubicin—thyroid cancer	0.00162	0.00164	CcSEcCtD
Regadenoson—Angiopathy—Doxorubicin—thyroid cancer	0.0016	0.00161	CcSEcCtD
Regadenoson—Immune system disorder—Doxorubicin—thyroid cancer	0.00159	0.00161	CcSEcCtD
Regadenoson—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00159	0.0016	CcSEcCtD
Regadenoson—Vision blurred—Epirubicin—thyroid cancer	0.00156	0.00158	CcSEcCtD
Regadenoson—Mental disorder—Doxorubicin—thyroid cancer	0.00154	0.00156	CcSEcCtD
Regadenoson—Ill-defined disorder—Epirubicin—thyroid cancer	0.00154	0.00155	CcSEcCtD
Regadenoson—Erythema—Doxorubicin—thyroid cancer	0.00154	0.00155	CcSEcCtD
Regadenoson—Dysgeusia—Doxorubicin—thyroid cancer	0.0015	0.00152	CcSEcCtD
Regadenoson—Malaise—Epirubicin—thyroid cancer	0.0015	0.00151	CcSEcCtD
Regadenoson—Syncope—Epirubicin—thyroid cancer	0.00149	0.0015	CcSEcCtD
Regadenoson—Palpitations—Epirubicin—thyroid cancer	0.00147	0.00148	CcSEcCtD
Regadenoson—Loss of consciousness—Epirubicin—thyroid cancer	0.00146	0.00147	CcSEcCtD
Regadenoson—Cough—Epirubicin—thyroid cancer	0.00145	0.00146	CcSEcCtD
Regadenoson—Vision blurred—Doxorubicin—thyroid cancer	0.00145	0.00146	CcSEcCtD
Regadenoson—Convulsion—Epirubicin—thyroid cancer	0.00144	0.00145	CcSEcCtD
Regadenoson—Hypertension—Epirubicin—thyroid cancer	0.00143	0.00144	CcSEcCtD
Regadenoson—Ill-defined disorder—Doxorubicin—thyroid cancer	0.00142	0.00144	CcSEcCtD
Regadenoson—Myalgia—Epirubicin—thyroid cancer	0.00141	0.00142	CcSEcCtD
Regadenoson—Chest pain—Epirubicin—thyroid cancer	0.00141	0.00142	CcSEcCtD
Regadenoson—Arthralgia—Epirubicin—thyroid cancer	0.00141	0.00142	CcSEcCtD
Regadenoson—Anxiety—Epirubicin—thyroid cancer	0.00141	0.00142	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.0014	0.00141	CcSEcCtD
Regadenoson—Discomfort—Epirubicin—thyroid cancer	0.0014	0.00141	CcSEcCtD
Regadenoson—Malaise—Doxorubicin—thyroid cancer	0.00138	0.0014	CcSEcCtD
Regadenoson—Syncope—Doxorubicin—thyroid cancer	0.00138	0.00139	CcSEcCtD
Regadenoson—Palpitations—Doxorubicin—thyroid cancer	0.00136	0.00137	CcSEcCtD
Regadenoson—Anaphylactic shock—Epirubicin—thyroid cancer	0.00135	0.00137	CcSEcCtD
Regadenoson—Loss of consciousness—Doxorubicin—thyroid cancer	0.00135	0.00136	CcSEcCtD
Regadenoson—Cough—Doxorubicin—thyroid cancer	0.00134	0.00135	CcSEcCtD
Regadenoson—Shock—Epirubicin—thyroid cancer	0.00133	0.00134	CcSEcCtD
Regadenoson—Convulsion—Doxorubicin—thyroid cancer	0.00133	0.00134	CcSEcCtD
Regadenoson—Nervous system disorder—Epirubicin—thyroid cancer	0.00133	0.00134	CcSEcCtD
Regadenoson—Hypertension—Doxorubicin—thyroid cancer	0.00133	0.00134	CcSEcCtD
Regadenoson—Tachycardia—Epirubicin—thyroid cancer	0.00132	0.00133	CcSEcCtD
Regadenoson—Skin disorder—Epirubicin—thyroid cancer	0.00132	0.00133	CcSEcCtD
Regadenoson—Hyperhidrosis—Epirubicin—thyroid cancer	0.00131	0.00132	CcSEcCtD
Regadenoson—Chest pain—Doxorubicin—thyroid cancer	0.00131	0.00132	CcSEcCtD
Regadenoson—Myalgia—Doxorubicin—thyroid cancer	0.00131	0.00132	CcSEcCtD
Regadenoson—Arthralgia—Doxorubicin—thyroid cancer	0.00131	0.00132	CcSEcCtD
Regadenoson—Anxiety—Doxorubicin—thyroid cancer	0.0013	0.00131	CcSEcCtD
Regadenoson—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.0013	0.00131	CcSEcCtD
Regadenoson—Discomfort—Doxorubicin—thyroid cancer	0.00129	0.0013	CcSEcCtD
Regadenoson—Hypotension—Epirubicin—thyroid cancer	0.00127	0.00128	CcSEcCtD
Regadenoson—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00125	0.00126	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00123	0.00124	CcSEcCtD
Regadenoson—Shock—Doxorubicin—thyroid cancer	0.00123	0.00124	CcSEcCtD
Regadenoson—Nervous system disorder—Doxorubicin—thyroid cancer	0.00123	0.00124	CcSEcCtD
Regadenoson—Insomnia—Epirubicin—thyroid cancer	0.00122	0.00123	CcSEcCtD
Regadenoson—Tachycardia—Doxorubicin—thyroid cancer	0.00122	0.00123	CcSEcCtD
Regadenoson—Skin disorder—Doxorubicin—thyroid cancer	0.00122	0.00123	CcSEcCtD
Regadenoson—Paraesthesia—Epirubicin—thyroid cancer	0.00122	0.00123	CcSEcCtD
Regadenoson—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00121	0.00122	CcSEcCtD
Regadenoson—Dyspnoea—Epirubicin—thyroid cancer	0.00121	0.00122	CcSEcCtD
Regadenoson—Somnolence—Epirubicin—thyroid cancer	0.0012	0.00121	CcSEcCtD
Regadenoson—Hypotension—Doxorubicin—thyroid cancer	0.00117	0.00118	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00117	0.00118	CcSEcCtD
Regadenoson—Pain—Epirubicin—thyroid cancer	0.00116	0.00117	CcSEcCtD
Regadenoson—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.00114	0.00115	CcSEcCtD
Regadenoson—Insomnia—Doxorubicin—thyroid cancer	0.00113	0.00114	CcSEcCtD
Regadenoson—Paraesthesia—Doxorubicin—thyroid cancer	0.00112	0.00113	CcSEcCtD
Regadenoson—Dyspnoea—Doxorubicin—thyroid cancer	0.00112	0.00113	CcSEcCtD
Regadenoson—Feeling abnormal—Epirubicin—thyroid cancer	0.00112	0.00113	CcSEcCtD
Regadenoson—Somnolence—Doxorubicin—thyroid cancer	0.00111	0.00112	CcSEcCtD
Regadenoson—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00111	0.00112	CcSEcCtD
Regadenoson—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.00108	0.00109	CcSEcCtD
Regadenoson—Urticaria—Epirubicin—thyroid cancer	0.00108	0.00108	CcSEcCtD
Regadenoson—Pain—Doxorubicin—thyroid cancer	0.00107	0.00108	CcSEcCtD
Regadenoson—Abdominal pain—Epirubicin—thyroid cancer	0.00107	0.00108	CcSEcCtD
Regadenoson—Feeling abnormal—Doxorubicin—thyroid cancer	0.00103	0.00104	CcSEcCtD
Regadenoson—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.00102	0.00103	CcSEcCtD
Regadenoson—Hypersensitivity—Epirubicin—thyroid cancer	0.000998	0.00101	CcSEcCtD
Regadenoson—Urticaria—Doxorubicin—thyroid cancer	0.000995	0.001	CcSEcCtD
Regadenoson—Abdominal pain—Doxorubicin—thyroid cancer	0.00099	0.000999	CcSEcCtD
Regadenoson—Asthenia—Epirubicin—thyroid cancer	0.000971	0.00098	CcSEcCtD
Regadenoson—Diarrhoea—Epirubicin—thyroid cancer	0.000926	0.000934	CcSEcCtD
Regadenoson—Hypersensitivity—Doxorubicin—thyroid cancer	0.000923	0.000931	CcSEcCtD
Regadenoson—Asthenia—Doxorubicin—thyroid cancer	0.000899	0.000906	CcSEcCtD
Regadenoson—Dizziness—Epirubicin—thyroid cancer	0.000895	0.000903	CcSEcCtD
Regadenoson—Vomiting—Epirubicin—thyroid cancer	0.000861	0.000868	CcSEcCtD
Regadenoson—Diarrhoea—Doxorubicin—thyroid cancer	0.000857	0.000864	CcSEcCtD
Regadenoson—Rash—Epirubicin—thyroid cancer	0.000854	0.000861	CcSEcCtD
Regadenoson—Dermatitis—Epirubicin—thyroid cancer	0.000853	0.00086	CcSEcCtD
Regadenoson—Headache—Epirubicin—thyroid cancer	0.000848	0.000855	CcSEcCtD
Regadenoson—Dizziness—Doxorubicin—thyroid cancer	0.000828	0.000835	CcSEcCtD
Regadenoson—Nausea—Epirubicin—thyroid cancer	0.000804	0.000811	CcSEcCtD
Regadenoson—Vomiting—Doxorubicin—thyroid cancer	0.000797	0.000803	CcSEcCtD
Regadenoson—Rash—Doxorubicin—thyroid cancer	0.00079	0.000796	CcSEcCtD
Regadenoson—Dermatitis—Doxorubicin—thyroid cancer	0.000789	0.000796	CcSEcCtD
Regadenoson—Headache—Doxorubicin—thyroid cancer	0.000785	0.000791	CcSEcCtD
Regadenoson—Nausea—Doxorubicin—thyroid cancer	0.000744	0.00075	CcSEcCtD
